L.A. Ruyatkina (1), M.Yu. Sorokin (2)

1) SBEI HPE “Novosibirsk State Medical University” of RMPH, Novosibirsk; 2) MBHCI NR City Clinical Hospital № 1, Novosibirsk
Proper glycemic control during pregnancy reduces the risk of maternal, fetal and neonatal complications. Therefore, insulin therapy is the mainstay of therapy of type 1 and 2 diabetes mellitus in pregnant women, as well as gestational diabetes. The purpose of the review - analysis of efficacy and safety of insulin detemir - the first basal insulin analogue approved for use during pregnancy (category B, FDA). The improved pharmacokinetic and pharmacodynamic profiles, low variability of action and great predictability of the clinical effect of insulin detemir provide the optimal glycemic control with a low risk of hypoglycemia and neutral effect on body weight. The clinical benefits of insulin detemir is confirmed by the results of clinical studies in pregnant women with diabetes mellitus that allows to recommend insulin detemir as a first-line therapy when choosing long-acting insulin for treatment of diabetes mellitus in pregnant women.


  1. Diabetes Care and Research in Europe. The Saint Vincent Declaration. Diabet Med. 1990;7(4):360.
  2. Тиселько А.В. Международный симпозиум «Диабет, Гипертония, Метаболический синдром и Беременность», 13–16 марта 2013 г., Флоренция, Италия. Сахарный диабет. 2013;(1):106–7.
  3. Jovanovic-Peterson L., Kitzmiller J.L., Peterson C.M. Randomized trial of human versus animal species insulin in diabetic pregnant women: improved glycemic control, not fewer antibodies to insulin, influences birth weight. Am. J. Obstet. Gynecol. 1992;167:1325–30.
  4. Rossetti P., Porcellati F., Fanelli C.G., Perriello G., Torlone E., Bolli G.B. Superiority of insulin analogues versus human insulin in the treatment of diabetes mellitus. Arch. Physiol. Biochem. 2008;114(1):3–10.
  5. Kitzmiller J.L., Block J.M., Brown F.M., Catalano P.M., Conway D.L., Coustan D.R., Gunderson E.P., Herman W.H., Hoffman L.D., Inturrisi M., Jovanovic L.B., Kjos S.I., Knopp R.H., Montoro M.N., Ogata E.S., Paramsothy P., Reader D.M., Rosenn B.M., Thomas A.M., Kirkman M.S. Managing preexisting diabetes for pregnancy: summary of evidence and consensus recommendations for care. Diabetes Care. 2008;31(5):1060–79.
  6. Key T.C., Giuffrida R., Moore T.R. Predictive value of early pregnancy glycohemoglobin in the insulintreated diabetic patient. Am. J. Obstet. Gynecol. 1987;156:1096–100.
  7. Mills J.L., Simpson J.L., Driscoll S.G., Jovanovic-Peterson L., Van Allen M., Aarons J.H., Metzger B., Bieber F.R., Knopp R.H., Holmes L.B., et al. Incidence of spontaneous abortion among normal women and insulin-dependent diabetic women whose pregnancies were identified within 21 days of conception. N. Engl. J. Med. 1988;319:1617–23.
  8. Rosenn B., Miodovnik M., Combs C.A., Khoury J., Siddiqi T.A. Preconception management of insulin-dependent diabetes: improvement of pregnancy outcome. Obstet. Gynecol. 1991;77:846–49.
  9. Casson I.F., Clarke C.A., Howard C.V., McKendrick O., Pennycook S., Pharoah P.O., Platt M.J., Stanisstreet M., van Velszen D., Walkinshaw S. Outcomes of pregnancy in insulin dependent diabetic women: results of a five year population cohort study. BMJ. 1997;315:275–78.
  10. Evers I.M., de Valk H.W., Visser G.H. Risk of complications of pregnancy in women with type 1 diabetes: nationwide prospective study in the Netherlands. BMJ. 2004;328:915.
  11. Macintosh M.C., Fleming K.M., Bailey J.A., Doyle P., Modder J., Acolet D., Golightly S., Miller A. Perinatal mortality and congenital anomalies in babies of women with type 1 or type 2 diabetes in England, Wales, and Northern Ireland: population based study. BMJ. 2006;333:177.
  12. Kitzmiller J.L., Buchanan T.A., Kjos S., Combs CюAю, Ratner R.E. Pre-conception care of diabetes, congenital malformations, and spontaneous abortions (ADA Technical Review). Diabetes Care 1996;19:514–41.
  13. Ray J.G., O’Brien T.E., Chan W.S. Preconception care and the risk of congenital anomalies in the offspring of women with diabetes mellitus: a meta-analysis. QJM. 2001;94:435–44.
  14. Kitzmiller J.L., Block J.M., Brown F.M., et al. Management of Preexisting Diabetes and Pregnancy. Alexandria, Virginia: American Diabetes Association. 2008.
  15. Suhonen L., Hiilesmaa V., Teramo K. Glycemic control during early pregnancy and fetal malformations in women with type 2 diabetes mellitus. Diabetologia. 2000;43:79–82.
  16. Temple R., Aldridge V., Greenwood R., Heyburn P., Sampson M., Stanley K. Association between outcome of pregnancy and glycemic control in early pregnancy in type 1 diabetes. BMJ. 2002;325:1275–76.
  17. Kerssen A., Evers I.M., de Valk H.W., Visser G.H. Poor glucose control in women with type 1 diabetes mellitus and ‘safe’ hemoglobin A1C values in the first trimester of pregnancy. J. Matern. Fetal. Neonatal. Med. 2003;13:309–13.
  18. Nielsen G.L., Moller M., Sorensen H.T. HbA1C in early pregnancy and pregnancy outcomes: a Danish population-based cohort study of 573 pregnancies in women with type 1 diabetes. Diabetes Care. 2006;29:2612–16.
  19. Gabbe S.G., Graves C. Management of diabetes mellitus complicating pregnancy. Obstet. Gynecol. 2003;102:857–68.
  20. Fetita L.S., Sobngwi E., Serradas P., Calvo F., Gautier J.F. Consequences of fetal exposure to maternal diabetes in offspring. J. Clin. Endocrinol. Metab. 2006;91:3714–24.
  21. Kauffman R.P. The Diabetes in Pregnancy Dilemma: Leading Change with Proven Solutions. J. Am. Med. Assoc. 2006;296:1530–31.
  22. Wu C.S., Nohr E.A., Bech B.H., et al. Long-term health outcomes in children born to mothers with diabetes: a population-based cohort study. PLoS. One. 2012;7(5):e36727.
  23. Mellemkjaer L., Olsen M.L., Sorensen H.T., Sоrensen H.T., Thulstrup A.M., Olsen J., Olsen J.H. Birth weight and risk of early-onset breast cancer (Denmark). Cancer Causes Control. 2003;14:61–4.
  24. Nilsen T.I., Romundstad P.R., Troisi R., Vatten L.J. Birth size and subsequent risk for prostate cancer: a prospective population-based study in Norway. Int. J. Cancer. 2005;113:1002–04.
  25. Nilsen T.I., Romundstad P.R., Troisi R., Potischman N., Vatten L.J. Birth size and colorectal cancer risk: a prospective population-based study. Gut. 2005;54:728–32.
  26. McCormack V.A., dos Santos Silva I., Koupil I., Leon D.A., Lithell H.O. Birth characteristics and adult cancer incidence: Swedish cohort of over 11,000 men and women. Int. J. Cancer. 2005;115(4):611–17.
  27. Heuch J.M., Heuch I., Akslen L.A., Kvale G. Risk of primary childhood brain tumors related to birth characteristics: a Norwegian prospective study. Int. J. Cancer. 1998;77:498–503.
  28. Von Behren J., Reynolds P. Birth characteristics and brain cancers in young children. Int. J. Epidemiol. 2003;32:248–56.
  29. Mogren I., Malmer B., Tavelin B., Damber L. Reproductive factors have low impact on the risk of different primary brain tumours in offspring. Neuroepidemiology 2003;22:249–54.
  30. Hjalgrim L.L., Westergaard T., Rostgaard K., Schmiegelow K., Melbye M., Hjalgrim H., Engels E.A. Birth weight as a risk factor for childhood leukemia: a meta-analysis of 18 epidemiologic studies. Am. J. Epidemiol. 2003;158:724–35.
  31. Krishnaveni G.V., Veena S.R., Hill J.C., Kehoe S., Karat S.C., Fall C.H. Intrauterine exposure to maternal diabetes is associated with higher adiposity and insulin resistance and clustering of cardiovascular risk markers in Indian children. Diabetes Care. 2010;33:402–04.
  32. Tam W.H., Ma R.C., Yang X., Li A.M., Ko G.T., Kong A.P., Lao T.T., Chan M.H., Lam C.W., Chan J.C. Diabetes Care; 2010. Glucose Intolerance and Cardiometabolic Risk in adolescent exposed to maternal Gestational Diabetes–a 15-year follow-up study. Diabetes Care. 2010;33(6):1382–84.
  33. Khoury J.C., Dolan L.M., Vandyke R., Rosenn B., Feghali M., Miodovnik M. Fetal development in women with diabetes: imprinting for a life-time? J. Matern. Fetal. Neonatal. Med. 2012;25(1):11–4.
  34. Jovanovic L., Knopp R.H., Brown Z., Conley M.R., Park E., Mills J.L., Metzger B.E., Aarons J.H., Holmes L.B., Simpson J.L. Declining insulin requirement in the late first trimester of diabetic pregnancy. Diabetes Care. 2001;24(7):1130–36.
  35. Evers I.M., ter Braak E.W., de Valk H.W., van Der Schoot B., Janssen N., Visser G.H. Risk indicators predictive for severe hypoglycemia during the first trimester of type 1 diabetic pregnancy. Diabetes Care. 2002;25(3):554–59.
  36. Scholtz H.E., van Niekerk M., Meyer B.H., Rosenkranz B. An assessment of the variability in the pharmacodynamics (glucose lowering effect) of HOE901 compared to NPH and ultralente human insulins using the euglycaemic clamp technique (Abstract). Diabetologia. 1999;42(Suppl. 1):A235.
  37. Ziel F.H., Davidson M.B., Harris M.D., Rosenberg C.S. The variability in the action of unmodified insulin is more dependent on changes in tissue insulin sensitivity than on insulin absorption. Diabet. Med. 1988;5(7):662–66.
  38. Jovanovic L., Pettitt D.J. Treatment with insulin and its analogs in pregnancies complicated by diabetes. Diabetes Care. 2007;30(Suppl. 2):S220–24.
  39. Kurtzhals P. Engineering predictability and protraction in a basal insulin analogue: the pharmacology of insulin detemir. Int. J. Obes. Relat. Metab. Disord. 2004;28(Suppl. 2):S23–8.
  40. Heinemann L., Sinha K., Weyer C., Loftager M., Hirschberger S., Heise T. Time-action profile of the soluble, fatty acid acylated, long-acting insulin analogue NN304. Diabet. Med. 1999;16(4):332–38.
  41. Pieber T.R., Plank J., Goerzer E., et al. Duration of action, pharmacodynamic profile and between-subject variability of insulin detemir in subjects with type 1 diabetes (Abstract). Diabetes. 2002;51(Suppl. 2):A53.
  42. Klein O., Lynge J., Endahl L., Damholt B., Nosek L., Heise T. Albumin-bound basal insulin analogues (insulin detemir and NN344): comparable time-action profiles but less variability than insulin glargine in type 2 diabetes. Diabetes Obes. Metab. 2007;9(3):290–99.
  43. Heise T., Nosek L., Ronn B.B., Endahl L., Heinemann L., Kapitza C., Draeger E. Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. Diabetes. 2004;53(6):1614–20.
  44. Russell-Jones D., Simpson R., Hylleberg B., Draeger E., Bolinder J. Effects of QD insulin detemir or neutral protamine hagedorn on blood glucose control in patients with Type 1 diabetes mellitus using a basal-bolus regimen. Clinical. Therapeutics. 2004;26(5):724–36.
  45. Tone A., Iseda I., Higuchi C., Tsukamoto K., Katayama A., Matsushita Y., Hida K., Wada J, Shikata K. Comparison of insulin detemir and insulin glargine on glycemic variability in patients with Type 1 and Type 2 diabetes. Exp. Clin. Endocrinol. Diabetes. 2010;118:320–24.
  46. abstract
  47. Vague P., Selam J.L., Skeie S., De Leeuw I., Elte J.W., Haahr H., Kristensen A., Draeger E. Insulin detemir is associated with more predictable glycemic control and reduced risk of hypoglycemia than NPH insulin in patients with type 1 diabetes on a basal-bolus regimen with premeal insulin aspart. Diabetes Care. 2003;26:590–96.
  48. De Leeuw I., Vague P., Selam J.L., Skeie S., Lang H., Draeger E., Elte J.W. Insulin detemir used in basal-bolus therapy in people with type 1 diabetes is associated with a lower risk of nocturnal hypoglycaemia and less weight gain over 12 months in comparison to NPH insulin. Diabetes Obes. Metab. 2005;7:73–82.
  49. Raslova K., Bogoev M., Raz I., Leth G., Gall M.A., Hancu N. Insulin detemir and insulin aspart: a promising basal-bolus regimen for type 2 diabetes. Diabetes Res. Clin. Pract. 2004;66:193–201.
  50. Tschritter O., Schafer S.A., Klett J., Pfafflin A., Haring H.U., Hennige A.M., Fritsche A. Insulin detemir causes increased symptom awareness during hypoglycaemia compared to human insulin. Diabetes Obes. Metab. 2009;11(11):1017–26.
  51. Fleischer J. Diabetic autonomic imbalance and glycemic variability. J. Diabetes Sci. Technol. 2012;6(5):1207–15.
  52. Standl E., Schnell O., Ceriello A. Postprandial hyperglycemia and glycemic variability: should we care? Diabetes Care. 2011;34(Suppl. 2):S120–7.
  53. Chang T.I., Horal M., Jain S.K., Wang F., Patel R., Loeken M.R. Oxidant regulation of gene expression and neural tube development: Insights gained from diabetic pregnancy on molecular causes of neural tube defects. Diabetologia. 2003;46:538–45.
  54. Li R., Chase M., Jung S.K., Smith P.J., Loeken M.R. Hypoxic stress in diabetic pregnancy contributes to impaired embryo gene expression and defective development by inducing oxidative stress. Am. J. Physiol. Endocrinol. Metab. 2005;289:E591–99.
  55. Agarwa A.l., Aponte-Mellado A., Premkumar B.J., Shaman A., Gupta S. The effects of oxidative stress on female reproduction: a review. Reprod. Biol. Endocrinol. 2012;10:49.
  56. Siegelaar S.E., Holleman F., Hoekstra J.B., DeVries J.H. Glucose variability; does it matter? Endocr. Rev. 2010;31(2):171–82.
  57. Johnson E.L. Glycemic variability in type 2 diabetes mellitus: oxidative stress and macrovascular complications. Adv. Exp. Med. Biol. 2012;771:139–54.
  58. Hartman I. Insulin analogs: impact on treatment success, satisfaction, quality of life, and adherence. Clin. Med. Res. 2008;6(2):54–67.
  59. International Diabetes Federation Clinical Guidelines Task Force. Global Guideline on Pregnancy and Diabetes. Brussels, Belgium: International Diabetes Federation; 2009. Available at: http://www.idf.org/global-guideline-pregnancy-and-diabetes. Accessed April 1, 2010.
  60. Stothard K.J., Tennant P.W.G., Bell R., Rankin J. Maternal overweight and obesity and the risk of congenital anomalies: A systematic review and meta-analysis. JAMA. 2009;301:636–50.
  61. Ramachenderan J., Bradford J., McLean M. Maternal obesity and pregnancy complications: a review. Aust. NZ. J. Obstet. Gynaecol. 2008;48:228–35.
  62. Dennedy M.C., Avalos G., O’Reilly M.W., O’Sullivan E.P., Dunne F.P. The impact of maternal obesity on gestational outcomes. Ir. Med. J. 2012;105(Suppl. 5):23–5.
  63. Schieve L.A., Cogswell M.E., Scanlon K.S. Trends in pregnancy weight gain within and outside ranges recommended by the Institute of Medicine in a WIC population. Matern. Child. Health J. 1998;2:111–16.
  64. Most O., Langer O. Gestational diabetes: maternal weight gain in relation to fetal growth, treatment modality, BMI and glycemic control. J. Matern. Fetal. Neonatal. Med. 2012;25(11):2458–63.
  65. Brown J.E., Murtaugh M.A., Jacobs D.R., Jr. Margellos H.C. Variation in newborn size according to pregnancy weight change by trimester. Am. J. Clin. Nutr. 2002;76:205–09.
  66. American Diabetes Association. Gestational diabetes mellitus (position statement). Diabetes Care. 2004;27(Suppl. 1):S88–90.
  67. Rae A., Bond D., Evans S., North F, Roberman B., Walters B. A randomized controlled trial of dietary energy restriction in the management of obese women with gestational diabetes. Aust. NZ. J. Obstet. Gynaecol. 2000;40:416–22.
  68. Tanentsapf I., Heitmann B.L., Adegboye A.R. Systematic review of clinical trials on dietary interventions to prevent excessive weight gain during pregnancy among normal weight, overweight and obese women. BMC Pregnancy Childbirth. 2011;11:81.
  69. Russell-Jones D., Khan R. Insulin-associated weight gain in diabetes: causes, effects and coping strategies. Diabetes Obes. Metab. 2007;9:799–812.
  70. Home P., Bartley P., Russell-Jones D., et al. Study to Evaluate the Administration of Detemir Insulin Efficacy, Safety and Suitability (STEADINESS) Study Group. Insulin detemir offers improved glycemic control compared with NPH insulin in people with type 1diabetes: a randomized clinical trial. Diabetes Care. 2004;27:1081–714.
  71. Hermansen K., Davies M., Derezinski T., Martinez Ravn G., Clauson P., Home P. A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetes Care. 2006;29:1269–74.
  72. Hordern S.M.V., Wright J.E., Umpleby A.M., Shojaee-Moradie F., Amiss J., Russell-Jones D.L. Comparison of the effects on glucose and lipid metabolism of equipotent doses of insulin detemir and NPH insulin with a 16-h euglycaemic clamp. Diabetologia. 2005;48:420–26.
  73. Hermansen K., Davies M. Does insulin detemir have a role in reducing risk of insulin-associated weight gain? Diabetes Obesity and Metabolism. 2007;9:209–17.
  74. Hallschmid M., Jauch-Chara K., Korn O., Mölle M., Rasch B., Born J., Schultes B., Kern W. Euglycemic infusion of insulin detemir compared with human insulin appears to increase direct current brain potential response and reduces food intake while inducing similar systemic effects. Diabetes. 2010;59:1101–07.
  75. Zachariah S., Sheldon B., Shojaee-Moradie F., Jackson N.C., Backhouse K., Johnsen S., Jones R.H., Umpleby A.M., Russell-Jones D.L. Insulin detemir reduces weight gain as a result of reduced food intake in patients with Type 1 diabetes. Diabetes Care. 2011;34:1487–91.
  76. Metzger B.E., Lowe L.P., Dyer A.R., Trimble E.R., Chaovarindr U., Coustan D.R., Hadden D.R., McCance D.R., Hod M., McIntyre H.D., Oats J.J., Persson B., Rogers M.S., Sacks D.A.; HAPO Study Cooperative Research Group. Hyperglycemia and adverse pregnancy outcomes. N. Engl. J. Med. 2008;358:1991–2002.
  77. Дедов И.И., Краснопольский В.И., Сухих Г.Т. от имени рабочей группы Российский национальный консенсус «Гестационный сахарный диабет: диагностика, лечение, послеродовое наблюдение». Сахарный диабет. 2012;(4):4–10.
  78. Lapolla A., Dalfra' M.G., Ragazzi E., et al. New International Association of the Diabetes and Pregnancy Study Groups (IADPSG) recommendations for diagnosing gestational diabetes compared with former criteria: a retrospective study on pregnancy outcome. Diabet. Med. 2011;28:1074–77.
  79. Nachum Z., Ben-Shlomo I., Weiner E., Shalev E. Twice daily versus four times daily insulin dose regimens for diabetes in pregnancy: randomised controlled trial. BMJ. 19996;319(7219):1223–27.
  80. Lapolla A., Di Cianni G., Bruttomesso D., Dalfrа M.G., Fresa R., Mello G., Napoli A., Romanelli T., Sciacca L., Stefanelli G., Torlone E., Mannino D. Use of insulin detemir in pregnancy: a report on 10 Type 1 diabetic women. Diabet. Med. 2009;26(11):1181–82.
  81. Sciacca L., Marotta V., Insalaco F., Tumminia A., Squatrito S., Vigneri R., Ettore G. Use of insulin detemir during pregnancy. Nutr. Metab. Cardiovasc. Dis. 2010;20(4):e15–6.
  82. Kurtzhals P., Schаffer L., Sоrensen A., Kristensen C., Jonassen I., Schmid C., Trüb T. Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes. 2000;49(6):999–1005.
  83. Hod M., Mathiesen E.R., Jovanoviс L., McCance D.R., Ivanisevic M., Durаn-Garcia S., Brоndsted L., Nazeri A., Damm P. A randomized trial comparing perinatal outcomes using insulin detemir or neutral protamine Hagedorn in type 1 diabetes. J. Matern. Fetal. Neonatal. Med. 2014;27(1):7–13.
  84. Mathiesen E.R., Hod M., Ivanisevic M., Duran Garcia S., Brоndsted L., Jovanovic L., Damm P., McCance D.R.; on behalf of the Detemir in Pregnancy Study Group. Maternal efficacy and safety outcomes in a randomized, controlled trial comparing insulin detemir with nph insulin in 310 pregnant women with Type 1 diabetes. Diabetes Care. 2012;35(10):2012–7.
  85. Hod M., Damm P., Kaaja R., Visser G.H., Dunne F., Demidova I., Hansen A.S., Mersebach H.;Insulin Aspart Pregnancy Study Group. Fetal and perinatal outcomes in type 1 diabetes pregnancy: a randomized study comparing insulin aspart with human insulin in 322 subjects. Am. J. Obstet. Gynecol. 2008;198:186.e1–7.
  86. PDF online

About the Autors

L.A. Ruyatkina – Doctor of Medical Sciences, Prof., SBEI HPE «Novosibirsk State Medical University" of RMPH, Novosibirsk
M.Yu. Sorokin - MBHCI NR City Clinical Hospital № 1, Novosibirsk

Similar Articles

Бионика Медиа